‘嗣’ means offspring and ‘道’ means a path. Together, 嗣道 represents the path to having a child. ‘嗣’ also means inheritance, while ‘道’ refers to the principles of conception. 嗣道优生 draws on the Western legend of the Stork bringing babies, bringing together renowned Chinese and international specialists to study fertility and reproduction.

嗣道优生 has long focused on reproductive health, preconception care, fertility preservation, and first- through third-generation IVF. It aims to address a broad range of modern fertility needs and has established coordinated fast-track services with several renowned hospitals in China. By combining care in China and abroad, it shortens overseas stays and provides families with comprehensive, integrated reproductive solutions.

嗣道 (Thailand) Fertility Hospital, operated by 嗣道, is located in central Bangkok and accredited by the Royal Thai College of Obstetricians and Gynaecologists. Its core specialist team, led by prominent Thai reproductive medicine expert Dr. 查宁, provides assisted reproduction, genetic disease screening and diagnosis, and other medical services. The hospital operates its own genetic testing center and is one of the few fertility institutions in Thailand with independently developed PGT technology and a laboratory system meeting European and US standards. It is committed to helping families have healthy babies.

1998 The founder began working in assisted reproduction in 1998.

2002 The founder returned to China in 2002 to serve as Greater China Sales Director for obstetrics, gynecology, and assisted reproduction at Organon Pharmaceutical Co., Ltd. Long-term collaboration with obstetrics, gynecology, and assisted reproduction providers in China and abroad created academic and technical exchange platforms for many prenatal diagnosis and fertility centers in China.

2009 Founded 和卓生物, focusing on prenatal screening, prenatal diagnosis, and reproductive health. The company independently developed single-cell isolation and testing technology. Based on genomics and cellomics, this high-tech enterprise develops research and clinical applications and provides many Grade III Class A hospitals in China with full-chain upstream, midstream, and downstream single-cell testing products and services.

2014 Founded 嗣道. 嗣道 (Thailand) Fertility Hospital is one of the few licensed Thai medical institutions managed to US laboratory-system standards and accredited by the Royal Thai College of Obstetricians and Gynaecologists.

November 2015 嗣道's first healthy baby conceived through third-generation IVF with whole-genome screening was born.

2016 As the only fertility center in Thailand offering both Karyomapping and preimplantation HLA matching, 嗣道 applied these technologies for many families affected by chromosomal disorders. That year, it was named a recommended fertility center by Thailand's Ministry of Public Health (MOPH) and a medical tourism promotion provider by the Thai Ministry of Public Health, while maintaining long-term technical and professional exchange with specialists in China and abroad.

2018 嗣道's 1,000th baby was born.

2019 Chinese national media reported the birth of the world's first baby in whom the imprinted-gene disorder Schaaf-Yang syndrome was prevented through preimplantation genetic testing. As an industry leader, 嗣道 used this technology to provide comprehensive solutions for families affected by genetic disorders.

August 2022 The world's first PGT-P boy conceived using family genetic information was born in China. As an industry leader, 嗣道 planned to use this technology to support families affected by polygenic disorders.

2023 Focused on building a consumer-platform database for women's fertility preservation, expanding from medical services into healthcare consumer services.

1998 The founder began working in assisted reproduction in 1998.

2002 The founder returned to China in 2002 to serve as Greater China Sales Director for obstetrics, gynecology, and assisted reproduction at Organon Pharmaceutical Co., Ltd. Long-term collaboration with obstetrics, gynecology, and assisted reproduction providers in China and abroad created academic and technical exchange platforms for many prenatal diagnosis and fertility centers in China.

2009 Founded 和卓生物, focusing on prenatal screening, prenatal diagnosis, and reproductive health. The company independently developed single-cell isolation and testing technology. Based on genomics and cellomics, this high-tech enterprise develops research and clinical applications and provides many Grade III Class A hospitals in China with full-chain upstream, midstream, and downstream single-cell testing products and services.

2014 Founded 嗣道. 嗣道 (Thailand) Fertility Hospital is one of the few licensed Thai medical institutions managed to US laboratory-system standards and accredited by the Royal Thai College of Obstetricians and Gynaecologists.

November 2015 嗣道's first healthy baby conceived through third-generation IVF with whole-genome screening was born.

2016 As the only fertility center in Thailand offering both Karyomapping and preimplantation HLA matching, 嗣道 applied these technologies for many families affected by chromosomal disorders. That year, it was named a recommended fertility center by Thailand's Ministry of Public Health (MOPH) and a medical tourism promotion provider by the Thai Ministry of Public Health, while maintaining long-term technical and professional exchange with specialists in China and abroad.

2018 嗣道's 1,000th baby was born.

2019 Chinese national media reported the birth of the world's first baby in whom the imprinted-gene disorder Schaaf-Yang syndrome was prevented through preimplantation genetic testing. As an industry leader, 嗣道 used this technology to provide comprehensive solutions for families affected by genetic disorders.

August 2022 The world's first PGT-P boy conceived using family genetic information was born in China. As an industry leader, 嗣道 planned to use this technology to support families affected by polygenic disorders.

2023 Focused on building a consumer-platform database for women's fertility preservation, expanding from medical services into healthcare consumer services.